In this context, EGFR-targeted agents have been extensively studied in SCCHN and these include cetuximab (an anti-EGFR antibody), gefitinib/erlotinib (selective EGFR inhibitors), and afatinib/dacomitinib (irreversible pan-HER inhibitors). Here, EGFR is linked to head and neck squamous cell carcinoma.